RajniAgarwalMD
Pediatric Hematology & Oncology • Palo Alto, CAPediatric Hematologic Oncology
Pediatric Stem Cell Transplant and Regenerative Medicine
Dr. Agarwal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
725 Welch Rd
Palo Alto, CA 94304Phone+1 650-497-8000Fax+1 650-497-8959
Education & Training
Cincinnati Children's Hospital Medical CenterResidency, Pediatrics, 1994 - 1995- Cincinnati Children's Hospital Medical CenterFellowship, Pediatric Hematology/Oncology, 1989 - 1992
M.G.M. Medical CollegeClass of 1983
Certifications & Licensure
CA State Medical License 2001 - 2025
OH State Medical License 1994 - 2001
Clinical Trials
- Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection Start of enrollment: 2014 Mar 01
- CD34+ Cell Enriched and T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Mismatched Related Donors or Borderline Organ Function Start of enrollment: 2014 May 01
- JSP191 Antibody Targeting Conditioning in SCID Patients Start of enrollment: 2017 Mar 20
Publications & Presentations
PubMed
- 42 citationsRelated and unrelated donor transplantation for β-thalassemia major: results of an international survey.Chunfu Li, Vikram Mathews, Soyoung Kim, Biju George, Kyle Hebert
Blood Advances. 2018-11-29 - 153 citationsNewborn screening for severe combined immunodeficiency and T-cell lymphopenia in California: Results of the first 2 yearsAntonia Kwan, Joseph A. Church, Morton J. Cowan, Rajni Agarwal, Neena Kapoor
The Journal of Allergy and Clinical Immunology. 2013-07-01 - 2 citationsAntiviral cellular therapy for enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation (ACES): a two-arm, open label phase II intervent...Michael D Keller, Patrick J Hanley, Yueh-Yun Chi, Paibel Aguayo-Hiraldo, Christopher C Dvorak
Nature Communications. 2024-04-18
Lectures
- Administration of Rimiducid Following Haploidentical BPX-501 Cells in Children with Malignant or Non-Malignant Disorders Who Develop Graft-Versus-Host-Disease (GvHD)Cl...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Administration of BPX-501 Following Αβ-T and B-Cell Depleted Haplo-HSCT in Children with Transfusion-Dependent Thalassemia2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Jasper Therapeutics Announces Upcoming Data Presentation on Lead Program, JSP191, at 61st American Society of Hematology (ASH) Annual Meeting & ExpositionDecember 9th, 2019
Using Antibody in Treatment of ‘Bubble Boy Disease’ Shows Early PromiseFebruary 28th, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
